Abstracts tagged "Inflammation"

Abstract Number: 1304 • ACR Convergence 2025
The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin – a multicenter study
Neta Berlak¹, Lydia Christodoulou², Gil Amarilyo³, Oded Scheuerman⁴, Irit Tirosh⁵, Eyal Kristal⁶, Ester Forer⁷, Amit Carmi⁸, Alon Kalter⁹ and Yoel Levinsky¹⁰, ¹Schneider children's medical center of Israel, Tel Aviv, Israel, ²Tel Hashomer, Periatric rheumatology unit, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, ⁴schneider children's meidcal center of Israel, Petah tikva, Israel, ⁵Tel Aviv universty, Ramat Gan, Israel, ⁶Soroka medical center Beer Sheva, Beer Sheva, Israel, ⁷Soroka medical center, Beer Sheva, Israel, ⁸Schneider children's meidcal center of Israel, Tel Aviv, Israel, ⁹Schneider children's medical center of ISrael, Petah Tikva, Israel, ¹⁰Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel
Background/Purpose: Fever of Unknown Origin (FUO) is a relatively common clinical challenge that is frequently referred for evaluation by pediatric rheumatologists. In many cases, it…
Abstract Number: 1016 • ACR Convergence 2025
Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
Ilana Usiskin¹, Lauren rusnak², Katherine Zhong³, Ying Qi⁴, Nicole Yang², Gregory McDermott⁵, Brittany Weber⁶ and Katherine Liao², ¹Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Heart failure (HF) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Prior work has suggested that higher levels of inflammation…
Abstract Number: 0562 • ACR Convergence 2025
Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Joseph F Merola¹, Philip J. Mease², Laura Coates³, Iain McInnes⁴, Peter Nash⁵, Alexis Ogdie⁶, Lihi Eder⁷, mitsumasa kishimoto⁸, Anna Beutler⁹, Konstantina Psachoulia⁹, Shihong Sheng¹⁰, Bei Zhou¹¹, Mehrdad Javidi¹², Chandni Valiathan¹², Charles Iaconangelo¹⁰, Ya-Wen Yang¹³, Arun Kannan¹³, Chetan S. Karyekar⁹ and Tasneam Shagroni⁹, ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Griffith University and U of Queensland, Maroochydore, Queensland, Australia, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Toronto, Toronto, ON, Canada, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Johnson & Johnson, Spring House, PA, USA, Spring House, ¹⁰Johnson & Johnson, Chesterbrook, PA, USA, Chesterbrook, ¹¹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹²Johnson & Johnson, San Diego, CA, USA, San Diego, ¹³Johnson & Johnson, San Diego, CA, USA, San Diego, CA
Background/Purpose: PsA affects ~20-30% of pts with PsO, causing articular inflammation/damage, and impaired health-related quality of life (HRQoL). ICO, a novel targeted oral peptide that…
Abstract Number: 0429 • ACR Convergence 2025
Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Xuemei Tang¹, Xiwen Luo², Xiya Luo¹, Mengwei Ding³, Xi Yang², Dawei Liu², Li Xu², Zhiyong Zhang², Yunfei An² and Xiaodong Zhao¹, ¹Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), ²Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), ³Big Data Center for Children’s Medical Care, Children’s Hospital of Chongqing Medical University, Chongqing, China., Chongqing, China (People's Republic)
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease. Some patients experiencing active disease due to inadequate responses to conventional treatments. Studies have demonstrated…
Abstract Number: 0105 • ACR Convergence 2025
Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
Guillaume LARID¹, Cassandre Dumonteix Moreau², Adrien JAMAI², Hanitriniaina Rabeony², Jean Claude LECRON², Elisabeth Gervais¹, Jean François JEGOU² and franck MOREL², ¹Poitiers University Hospital - Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France, ²Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France
Background/Purpose: Psoriatic disease is a systemic inflammatory condition which encompasses both cutaneous psoriasis (PsO), psoriatic arthritis (PsA) and multiple comorbidities. The chronic Imiquimod (IMQ) induced…
Abstract Number: 2425 • ACR Convergence 2025
Neutrophil Transcriptomics in SLE: Exploring Intrinsic, Ex Vivo Adaptation, and CAR-T Cell Therapy-Induced Changes
Ehsan Dehdashtian¹, Stefania Gallucci², Guangnan Hu³, Dominic Borie⁴ and Roberto Caricchio⁵, ¹UMass Chan Medical School, Worcester, MA, ²Temple University School of Medicine, Worcester, MA, ³UMass Chan School of Medicine, Worcester, MA, ⁴Kyverna Therapeutics, Emeryville, CA, ⁵University of Massachusetts Chan Medical School, Worcester, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulation of the adaptive and innate immune systems. Neutrophils, key players in innate immunity,…
Abstract Number: 2011 • ACR Convergence 2025
A Phase 1 placebo controlled, single (SAD) and multiple dose escalation (MAD) safety and pharmacokinetic (PK) study of a novel colchicine analogue ABP-745 in healthy volunteers (HV)
ullrich schwertschlag¹, Roy Wu², yan yang³ and William Shi⁴, ¹Atom Therapeutics, PALO ALTO, CA, ²Atom Bioscience, San Francisco, CA, ³Atom Therapeutics, Suzhou, China (People's Republic), ⁴Atom Therapeutics, Newark, CA
Background/Purpose: ABP-745 is a novel colchicine analogue in development as an anti-inflammatory agent for the treatment of acute gout and other chronic inflammatory conditions. In…
Abstract Number: 1654 • ACR Convergence 2025
A Dual Inhibitor of TAK1 and MAP4K2, NG25, Suppresses Cytokine-Driven Inflammation in Juvenile Idiopathic Arthritis Synovial Fibroblasts
Meena Afroze Shanta¹ and Salahuddin Ahmed², ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University, Spokane, WA
Background/Purpose: Chronic synovitis is a hallmark of juvenile idiopathic arthritis (JIA), and synovial fibroblasts are major perpetrators of inflammation and tissue destruction. Thus, we tested…
Abstract Number: 1207 • ACR Convergence 2025
Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Jesus Valencia¹, Will Kelly¹, Sean Tackett², Amanda Finney¹, Jemima Albayda¹, Julie Paik³, Lisa Christopher-Stine¹ and Chris Mecoli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by cutaneous manifestations and proximal muscle inflammation.1,2 Notably, the clinical course of muscular and cutaneous disease…
Abstract Number: 1008 • ACR Convergence 2025
Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Hasan Satis¹, Umut Kalyoncu², Gizem Ayan³, Ali Aykut Fidanci⁴, Mustafa Mahir Ulgu⁴, Naim Ata⁴, Suayip Birinci⁴, Mehmet Koçak⁵ and Ahmet Gul⁶, ¹University of Health Sciences, Abdurrahman Yurtaslan Oncology Hospital, Rheumatology, Ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Ankara Research and Training Hospital, Ankara, Turkey, ⁴Ministry of Health, Ankara, Turkey, ⁵Medipol University, Istanbul, Turkey, ⁶Istanbul University, Istanbul, Turkey
Background/Purpose: While two trials with colchicine have demonstrated its efficacy in reducing the risk of cardiovascular events, a more recent study showed no significant impact…
Abstract Number: 0551 • ACR Convergence 2025
Enthesitis Beyond the Surface: Ultrasonographic Unmasking of Preclinical Psoriatic Arthritis in Cutaneous Psoriasis
Victor Cazac¹ and Eugeniu Russu², ¹Norwalk Hospital, Nuvance Health, Connecticut, ²"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops insidiously from psoriasis (PsO), with enthesitis representing a critical initial site of inflammation. Musculoskeletal ultrasonography (MSUS) enables the identification of…
Abstract Number: 0360 • ACR Convergence 2025
Assessing Content Validity of a New Questionnaire Evaluating Glucocorticoid Toxicity
Timothy Howell¹, anne Skalicky², Louis Matza¹, John Stone³, Martha Stone⁴, Vijayaraghava Rao⁵ and Glenn Phillips⁵, ¹evidera, Washington, DC, ²evidera, Seattle, WA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Steritas, LLC, Concord, MA, ⁵argenx, Boston, MA
Background/Purpose: While glucocorticoids (GCs) are commonly used to treat a range of inflammatory diseases, the burden of toxicities associated with these medications is significant. The…
Abstract Number: 0100 • ACR Convergence 2025
Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Beatriz Vellón-García¹, Gema Dolores García-Delgado², Adrián Llamas Urbano³, Yas Hanaee³, Pedro Ortiz Buitrago⁴, Christian Merlo⁵, Maria del carmen abalos-aguilera⁵, julio Manuel Martinez Moreno⁶, Iván Arias de la Rosa⁷, María Dolores López-Montilla⁸, Rafaela Ortega-Castro⁹, Jerusalén Calvo¹⁰, Lourdes Ladehesa¹¹, Clementina López Medina¹², María Ángeles Puche-Larrubia¹³, Nuria Barbarroja¹⁴, Eduardo Collantes estévez¹⁵, Alejandro Escudero-contreras⁵, Chary López pedrera¹⁶, Jose manuel Villalba¹⁷ and Carlos Pérez Sánchez¹⁸, ¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ²Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, ³Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁶Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain, Cordoba, Spain, ⁷IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, ⁸Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹⁰IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹¹IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ¹³Reina Sofia University Hospital, Granada, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁵Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹⁷Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to:Characterize the NAD+ metabolome in CIRDs and their association with clinical traits.Evaluate the impact of TNFi therapy on NAD+ metabolome alterations.Test…
Abstract Number: 2345 • ACR Convergence 2025
Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
Dafna D. Gladman¹, Lihi Eder², Carlo Selmi³, Philip J. Mease⁴, Alexis Ogdie⁵, Karissa Lozenski⁶, Mohamed Sharaf⁷, Emmanouil Rampakakis⁸, Laura Pina Vegas⁹ and Laura Coates¹⁰, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Humanitas University, Milan, Italy, ⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Johnson & Johnson, Horsham, PA, ⁷Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ⁸JSS Medical Research, Montréal, QC, Canada, ⁹Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), University Paris-Est Créteil Val de Marne, Créteil, France; Rheumatology, Hospital Henri Mondor, AP-HP, Créteil, France, Creteil, France, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Previous research has shown that women with psoriatic arthritis (PsA) often have lower rates of clinical response to medication but less severe radiographic joint…
Abstract Number: 2010 • ACR Convergence 2025
Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli
Tony Merriman¹, Christopher Hall², Annie Chien², Richard Reynolds³, Jeffrey Edberg³, Pariyaphon Lertprachakwong³, Hannah Darroch⁴, Megan Leask⁴, Mumin Ozturk⁵, Brenda Kischkel⁵, Nicholas Sumpter⁵, Leo Joosten⁵ and Nils Asmann⁵, ¹University of Alabama at Birmingham, Homewood, AL, ²University of Aucklabd, Auckland, New Zealand, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Otago, Dunedin, New Zealand, ⁵Radboud University Medical College, Nijmegen, Netherlands
Background/Purpose: CSF1 and CSF1R encode a secreted and membrane-bound cytokine and its receptor controlling differentiation of monocytes into macrophages and inflammatory activity of macrophages. There…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].